Included in protocols where oxidative stress management is the primary goal, with the evidence limitation disclosed to patients
doi: 10.1042/BSR20211634 20 ZhangALuoRLiJMiaoRAnHYanXet al
It did not lift dark spots immediately (although the average time for this is 6 weeks) - so I might have to keep on it to see if there is dramatic difference and update
TB-500s systemic distribution supports healing throughout the thoracic region while BPC-157 provides targeted support at the primary injury site
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read 5-Amino-1MQ Peptide: Benefits, Uses, Side Effects, Dosage, and Research
It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby